Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development.
about
Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malariaSub-Saharan red cell antigen phenotypes and glucose-6-phosphate dehydrogenase deficiency variants in French GuianaTafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to dateGlucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malariaThe impact of phenotypic and genotypic G6PD deficiency on risk of plasmodium vivax infection: a case-control study amongst Afghan refugees in PakistanHigh risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiencyGlucose-6-phosphate dehydrogenase deficiency in an endemic area for malaria in Manaus: a cross-sectional survey in the Brazilian AmazonGlucose-6-Phosphate Dehydrogenase Deficiency and Haemoglobin Drop after Sulphadoxine-Pyrimethamine Use for Intermittent Preventive Treatment of Malaria during Pregnancy in Ghana - A Cohort StudyActivity of Herbal Medicines on Plasmodium falciparum Gametocytes: Implications for Malaria Transmission in GhanaG6PD deficiency in Latin America: systematic review on prevalence and variantsTackling the malaria problem in the South-East Asia Region: need for a change in policy?The challenges of introducing routine G6PD testing into radical cure: a workshop report.Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine.Resistance to therapies for infection by Plasmodium vivaxImpact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility.Nutritional status of young children with inherited blood disorders in western Kenya.Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies.Glucose-6-phosphate dehydrogenase deficiency in people living in malaria endemic districts of NepalIrreversible AE1 tyrosine phosphorylation leads to membrane vesiculation in G6PD deficient red cellsG6PD deficiency alleles in a malaria-endemic region in the Western Brazilian AmazonIn Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individualsMalaria in Brazil, Colombia, Peru and Venezuela: current challenges in malaria control and elimination.Malaria rapid diagnostic tests: Plasmodium falciparum infections with high parasite densities may generate false positive Plasmodium vivax pLDH linesUncertainty in mapping malaria epidemiology: implications for controlEffectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.Elimination therapy for the endemic malarias.The reality of using primaquine.Primaquine: the risks and the benefitsOperational strategies to achieve and maintain malaria elimination.Methemoglobinemia caused by 8-aminoquinoline drugs: DFT calculations suggest an analogy to H4B's role in nitric oxide synthase.A high-throughput screen targeting malaria transmission stages opens new avenues for drug developmentEnantioselective metabolism of primaquine by human CYP2D6.Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the GambiaChemotherapeutics challenges in developing effective treatments for the endemic malariasPlasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa.Design and Synthesis of Novel Hybrid Molecules against Malaria.G6PD deficiency in male individuals infected by Plasmodium vivax malaria in the Brazilian Amazon: a cost study.Predicting the Kinetic Properties Associated with Redox Imbalance after Oxidative Crisis in G6PD-Deficient Erythrocytes: A Simulation StudyFrequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trialsNoninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells
P2860
Q21143739-FF3A6B79-AAF6-4F1E-B5B6-AE31D2E64E3DQ24570079-8659BF08-6BA0-4EC1-A8A9-D55BA3C3763EQ26741307-44863515-F6B9-4CCC-A28E-29699EE572DAQ28265711-C213C977-ECD0-429E-8D46-5F8BE224D4C5Q28474079-7F53C66A-86CC-4FF4-88B5-6C5886B3C8BEQ28474365-73CF7D4F-B078-47C5-A109-7FB1A00C6899Q28475311-1A45455E-53C4-4910-9AFA-76A235254DF7Q28547654-AE5F310E-4C44-452B-BF43-3E0383158CABQ28550911-BEF814A4-8F4F-4AA1-BCDE-E141077E7932Q29353696-1FAE93C7-2011-4B82-8178-9DD6F6015731Q30597566-5DD9D201-7973-4147-9978-3C77D42F061DQ30666192-EFEE7B28-6596-452D-82FB-A3B06F97A61CQ33400434-E8D00FFA-C496-41CE-8B49-D1DAB2A9C70EQ33481576-8EB7B73A-2843-4287-8B3C-1110E80C7D26Q33507529-00B79360-5D7A-40F4-9111-3A613A6A2CFAQ33588574-39E35B99-6398-41F8-B8F3-471047C4D747Q33626090-B730887F-2C9A-429C-8BE7-ABB975BBAF73Q33721887-557EDE99-BDF2-4952-A08A-A03EE92750ECQ33796703-7CEAEE43-386B-482D-B2AB-D845723D2C29Q33801271-DA3A6DA3-95D8-4A80-BF1B-7DDF792FD95BQ33826283-8F8387C5-ED0A-4DBE-B4A1-AC453355B409Q33870033-1A86FA8F-6D1D-422C-BB8A-10C3404F4868Q34025937-8E55CB09-80DF-4D9B-AB39-3CC6263A3FAAQ34030351-0D0F2F74-17DA-4AFA-96ED-2A18CEDB8C60Q34164652-5F5D7D72-FF0A-4549-9A7B-51465D65F796Q34194828-D62978A6-2B43-4BF7-8534-02022599C65AQ34478012-C9BD52B5-6684-4427-8C72-3C0AAA061F25Q34503631-E5608ADB-81B7-4A6A-9DD1-278EA771C46BQ34568019-C327338C-602A-4599-9BB5-7B21B600C393Q34757973-C38CB652-B780-4E0E-B759-5B805D1FF6E7Q34833899-4EBF6587-D2D8-4B14-9BCF-13C4608F7E9BQ34994945-9E18F464-BD39-4060-A59E-2E2222A79698Q35031434-8305F0DA-F59F-4C74-8E86-C882853D8F57Q35095657-7E14E839-8B92-4617-BF3B-FD55981C3989Q35102950-4B4FFEF9-8607-4736-B73E-192DE9221127Q35103178-F7B4485B-D9D9-4D50-A926-C09A557D89B7Q35237781-A429442E-FCC8-4CC9-8833-9A42923CB0FBQ35250817-89F7C899-1ABE-4F0B-956B-B32E56AB1B6FQ35283214-09B31ED7-A928-4350-925C-75ACC34A81A0Q35328856-568B246B-F358-4F99-A5F1-F41CD4F38E53
P2860
Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development.
@en
type
label
Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development.
@en
prefLabel
Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development.
@en
P2093
P1476
Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development
@en
P2093
Ernest Beutler
G6PD Deficiency Working Group
Stephan Duparc
P304
P356
10.4269/AJTMH.2007.77.779
P407
P577
2007-10-01T00:00:00Z